This protocol covers anaplastic astrocytoma (CNS WHO grade 3) in adult patients defined by a specific molecular profile: IDH mutation present, with 1p19q codeletion absent. This combination of features places the tumour in a distinct clinical category that guides treatment selection.
Astrocytoma (anaplastic, CNS WHO grade 3) with IDH mutation present and 1p19q codeletion absent (non-codeleted), in adults. Molecular testing confirming both IDH mutation status and 1p19q codeletion status is central to identifying this subgroup and determining the appropriate treatment pathway.
Evidence-based guidelines support a combined modality approach — radiation therapy together with adjuvant chemotherapy. The full protocol specifies the regimen, sequence, eligibility criteria, and supporting evidence.
Full regimen details available in the complete protocol ↓DOI: 10.1093/neuonc/noab279
People with astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 should be offered RT with adjuvant TMZ (Type: evidence-based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: strong).
View source ↗